RxDoctor Payments Data

John Nwofia, MD

Pain Medicine · Brentwood, TNNPI 1588777445

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,733 of the $16,910 with a category attached, or 81.2%. Abbott accounts for 60.9% of it on its own, with 20 other manufacturers making up the rest.

$16,910in general payments, 2019–2025

Across 485 payments — averaging $34.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Boston Scientific$3K
  • Spinefrontier, Inc.$1K
  • Medtronic$757
  • Nevro Corp.$356
  • SPR Therapeutics, Inc$255
  • plus $917 from 15 others

What the payments were for

  • Travel & lodging$3,17719%
  • Food & beverage$13,73381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,910 in reported general payments places this provider in the 85th percentile of 112 pain medicine providers in Tennessee.

See all pain medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$100,605
Medicare patients
206
Services billed
2,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen687$22,650
ZtlidoLidocaine24$16,145
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen524$15,809
Gabapentin487$6,650
Pregabalin213$5,322
Tizanidine Hcl304$4,312
Lidocaine49$4,209
Oxycodone Hcl134$2,546
Morphine Sulfate ErMorphine Sulfate97$2,248
Fentanyl24$2,178
Diclofenac Sodium51$2,173
Lubiprostone17$2,058
Cyclobenzaprine Hcl126$1,678
Methocarbamol113$1,497
Duloxetine Hcl77$1,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$13$16,14524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 pain medicine providers in Tennessee.

Other pain medicine in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →